Search - tctmd.com

Displaying 901 - 920 of 1378

Sort: Relevancy | Date

News Industry News

ARIAD and Medinol Announce Initiation of Two Registration Trials of the NIRsupreme™ Ridaforolimus-Eluting Stent for Use in Coronary Artery Disease

January 13, 2014

News Daily News

EES Reduce Revascularization vs. BMS Regardless of Kidney Disease Severity

January 09, 2014

News Daily News

Bioresorbable Scaffolds Show Promise in Select STEMI Patients

Yael L. Maxwell

January 09, 2014

News Daily News

Los SLF de 1ª Generación son Menos Rentables que SMD + Rapamicina Oral a los 5 Años

January 06, 2014

News Daily News

Meta-analysis: Newer-Generation DES Safe, Effective vs. BMS in STEMI

January 01, 2014

News Daily News

Meta Análisis: Comparados con los SMD, los SLF de Última Generación son Seguros y Eficaces contra los cuadros de STEMI

January 01, 2014

News Daily News

Meta-analysis: CABG Bests PCI for Long-term Morbidity, Mortality in Multivessel CAD

Yael L. Maxwell

December 30, 2013

News Daily News

Analysis Shows DES Reduce TVR but Not Mortality vs. BMS in Extreme Elderly

December 30, 2013

News Daily News

Second-Generation DES the Better Choice for STEMI Patients

December 09, 2013

News Daily News

Los SLF de 2ª Generación son la Mejor Opción para Pacientes víctimas de STEMI

December 09, 2013

News Daily News

IVUS Guidance Reduces Stent Thrombosis, MACE Compared to Angiography

December 08, 2013

News Daily News

El Guiado mediante IVUS Reduce la Trombosis del STENT y los MACE comparado con la Angiografía

December 08, 2013

News Industry News

Alvimedica merges with CID, Italy's leading high tech company specialized in cardiology

November 19, 2013

News Conference News TCT 2013

Meta-analysis: Most DES Safer Than BMS, Biodegradability Offers No Extra Benefit

November 03, 2013

Presentation TCT 2013

FREEDOM: A Prospective, Randomized Trial of First Generation Drug-Eluting Stents vs. CABG in Insulin- and Noninsulin-Treated Diabetic Patients

Presenter: George Dangas

October 31, 2013

Presentation TCT 2013

Drug-Eluting Balloons vs. Everolimus-Eluting Stents for Treatment of In-Stent Restenosis

Presenter: J?rg Schr?der

October 31, 2013

News Industry News

Study Examines the Impact of Insulin Treatment Status in Diabetic Patients with Multivessel Coronary Artery Disease

October 31, 2013

News Industry News

New Study Demonstrates Potential Benefits of Shorter-Term Dual Antiplatelet Therapy in Patients Treated With a Second Generation Drug-Eluting Stent

October 31, 2013

News Conference News TCT 2013

DUTCH PEERS: Third-Generation Stents Equivalent, Effective

October 31, 2013

News Industry News

Comparison of Two Third-Generation Drug-Eluting Stents Establishes Comparable Safety and Efficacy; Demonstrates Non-Inferiority of Newest Zotarolimus-Eluting Stent

October 31, 2013

Advertisement

ARIAD and Medinol Announce Initiation of Two Registration Trials of the NIRsupreme™ Ridaforolimus-Eluting Stent for Use in Coronary Artery Disease

EES Reduce Revascularization vs. BMS Regardless of Kidney Disease Severity

Bioresorbable Scaffolds Show Promise in Select STEMI Patients

Los SLF de 1ª Generación son Menos Rentables que SMD + Rapamicina Oral a los 5 Años

Meta-analysis: Newer-Generation DES Safe, Effective vs. BMS in STEMI

Meta Análisis: Comparados con los SMD, los SLF de Última Generación son Seguros y Eficaces contra los cuadros de STEMI

Meta-analysis: CABG Bests PCI for Long-term Morbidity, Mortality in Multivessel CAD

Analysis Shows DES Reduce TVR but Not Mortality vs. BMS in Extreme Elderly

Second-Generation DES the Better Choice for STEMI Patients

Los SLF de 2ª Generación son la Mejor Opción para Pacientes víctimas de STEMI

IVUS Guidance Reduces Stent Thrombosis, MACE Compared to Angiography

El Guiado mediante IVUS Reduce la Trombosis del STENT y los MACE comparado con la Angiografía

Alvimedica merges with CID, Italy's leading high tech company specialized in cardiology

Meta-analysis: Most DES Safer Than BMS, Biodegradability Offers No Extra Benefit

FREEDOM: A Prospective, Randomized Trial of First Generation Drug-Eluting Stents vs. CABG in Insulin- and Noninsulin-Treated Diabetic Patients

Drug-Eluting Balloons vs. Everolimus-Eluting Stents for Treatment of In-Stent Restenosis

Study Examines the Impact of Insulin Treatment Status in Diabetic Patients with Multivessel Coronary Artery Disease

New Study Demonstrates Potential Benefits of Shorter-Term Dual Antiplatelet Therapy in Patients Treated With a Second Generation Drug-Eluting Stent

DUTCH PEERS: Third-Generation Stents Equivalent, Effective

Comparison of Two Third-Generation Drug-Eluting Stents Establishes Comparable Safety and Efficacy; Demonstrates Non-Inferiority of Newest Zotarolimus-Eluting Stent

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content